Synthesis and antitumor activity of 1-[2-(chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1- ureas as potent anticancer agents

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2525-2532

  Motohashi, Noboru ^a   Kawase, Masami ^b   Kurihara, Teruo ^b   Hevér, Anikó ^c   Nagy, Szilvia ^c   Ocsocvszki, Imre ^c   Tanaka, Masaru ^c   Molnár, Joseph ^c  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

10 N (phthalimido)alkyl 2 substituted 10H phenothiazines,1 (2 ; Antitumor activity; chloroethyl) 3 (2 substituted 10H phenothiazin 10 yl)alkyl 1 ureas; Structure activity relationship

Indexed keywords

PHENOTHIAZINE DERIVATIVE; UREA DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; GROWTH INHIBITION; LYMPHOMA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; HUMANS; LEUKEMIA L5178; MICE; PHENOTHIAZINES; PHENYLUREA COMPOUNDS;

EID: 0029966193     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Motohashi N: Antitumor activities of phenothiazines (Phenothiazine Oncology) In: Gupta RR (ed), Phenothiazines and 1,4-Benzothiazines, Bioactive Molecules. Vol 4, Elsevier, 1988, pp 705-770.
2. Motohashi N, Kamata K and Meyer R: Interaction of chlorpromazine with DNA. Anticancer Res 10: 1611-1614, 1990.
3. Jones GRN: Cancer therapy: Phenothiazines in an unexpected role. Tumori 71: 563-569, 1985.
4. Ghosh N and Chattopadhyay U: Enhancement of immune response by phenothiazine administration in vivo. In Vivo 7: 435-440, 1993.
5. Krieglstein J, Meiler W and Staab J: Hydrophobic and ionic interactions of phenothiazine derivatives with bovine serum albumin. Biochem Pharmacol 21: 985-997, 1972.
6. 2+)-ATPase and its antagonism by phenothiazines. Mol Pharmacol 18: 253-258, 1980.
7. Hinds TR, Raess BU and Vincenzi FF: Plasma membrane calcium (2+) ion transport: antagonism by several potential inhibitors. J Membrane Biol 58: 57-65, 1981.
8. (a) Vincenzi FF: Regulation of a plasma membrane calcium pump: a speculative model. Ann NY Acad Sci 307: 229-231, 1978.
9. (b) Vincenzi FF, Raess BU, Larsen FL, Jung NSGT and Hinds TR: The plasma membrane calcium pump: a potential target for drug action. Pharmacologist 20 (3): 257 (abstract), 1978.
10. (a) Raess BU and Vincenzi FK: A semi-automated method for the determination of multiple membrane ATPase activities. J Pharmacol Methods 4(3): 273-283, 1980.
11. 2+ transport: Inhibition by trifluoroperazine. Pharmacologist 21: 697, 1929.
12. Rasmussen CD and Means AR: Calmodulin is involved in regulation of cell proliferation. EMBO J 6: 3961-3968, 1987.
13. Hait WN and Lazo JS: Calmodulin: A potential target for cancer chemotherapeutic agents. J Clin Oncol 4: 994-1012, 1986.
14. Akiyama S, Cornwell MM, Kuwano M, Pastan I and Gottesman MM: Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144-147, 1988.
15. Ganapathi R and Grabowski D: Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoroperazine. Cancer Res 43: 3696-3699, 1983.
16. Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879-2887, 1987.
17. Fojo A, Akiyama S, Gottesman MM and Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007, 1985.
18. Cornwell MM, Safa AR, Felsted RL, Gottesman MM and Pastan I: Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 83: 3847-3850, 1986.
19. Jungnelius U, Ridderström M, Hansson J, Ringborg U and Mannervik B: Similar toxic effect of 1,3-bis(2-chloroethyl)-1-nitrosourea on lymphocytes from human subjects differing in the expression of glutathione transferase M1-1. Biochem Pharmacol 47: 1777-1780, 1994.
20. Kohn KW, Erickson LC and Laurent G: DNA alkylation, crosslinking and repair. INSERM Symposium 19: 33-48, 1981.
21. Kohn KW: Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosoureas and other 1-(2-haloethyl)-Initrosoureas. Cancer Res 37: 1450-1454, 1977.
22. Ludlum DB and Tong WP: Modification of DNA and RNA bases by the nitrosoureas. INSERM Symposium 19: 21-31, 1981.
23. Lin G, Midha KK and Hawes EM: Synthesis of the piperidinone metabolites of piperidine type phenothiazine antipsychotic drugs via Ruthenium tetroxide oxidation. J Heterocyclic Chem 28: 215-219, 1991.
24. Tsujihara K, Ozeki M, Morikawa T and Arai Y: A new class of nitrosoureas. I. Synthesis and antitumor activity of 1-(2-chloroethyl)-3,3-disubstituted-1-nitrosoureas having a hydroxyl group at the ß-position of the substituents. Chem Pharm Bull (Japan) 29: 2509-2515, 1981.
25. Fujii K: Studies on the syntheses of phenothiazine derivatives. 11. On the reduction of 10-ß-cyanoethylphenothiazines. Yakugaku Zasshi (in Japanese) 76: 640-644, 1956.
26. Björksten B and Quie PG: Inhibition of human neutrophil chemotaxis in vitro by phenothiazines and related compounds. Infect Immun 14: 948-950, 1976.
27. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV and Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4486-4490, 1988.
28. Weaver JL, Szabo G, Pine PS, Gottesman MM, Goldenberg S and Aszalos A: The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 54: 456-461, 1993.
29. Kessel D: Exploring multidrug resistance using Rhodamine 123. Cancer Commun 1: 145-149, 1989.
30. Maron DM and Ames BN: Revised methods for the Salmonella mutagenicity test. Mutation Res 113: 173-215, 1983.
31. Ullrich SJ, Mercer WE and Appella E: Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene 7: 1635-1643, 1992.
32. Milner J and Watson JV: Addition of fresh medium induces cell cycle and conformation changes in p53, a tumor suppressor protein. Oncogene 5: 1683-1690, 1990.